# Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy

> **NCT06003881** · — · APPROVED_FOR_MARKETING · sponsor: **Regeneron Pharmaceuticals**

## Conditions studied

- CD55-Deficient Protein-Losing Enteropathy

## Interventions

- **DRUG:** Pozelimab

## Key facts

- **NCT ID:** NCT06003881
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06003881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06003881, "Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06003881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*